Company: GANX
Filing Date: 2025-07-17
Form Type: 8-K
Source: 0001104659-25-068530
Chunk: 0

Company: Gain Therapeutics, Inc.
Filing Date: 2025-07-17
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive Agreement.

On July 16, 2025, Gain Therapeutics, Inc., a Delaware corporation (the
“ Company”), entered into an underwriting agreement (the “ Underwriting Agreement”) with Newbridge
Securities Corporation, as underwriter (the “ Underwriter”), relating to the offering, issuance and sale of an aggregate
of (i) 4,501,640 shares of the Company’s common stock, par value $0.0001 per share (“ Common Stock”) and (ii)
warrants to purchase 2,250,820 shares of Common Stock (the “ Warrants” and the shares of Common Stock underlying the
Warrants, the “ Warrant Shares”) for aggregate gross proceeds of approximately $7.0 million (the “ Offering”).
The Warrants were offered and sold at the rate of one Warrant to purchase one share of Common Stock for every two shares of Common Stock
purchased in the Offering. The public offering price for each set of two shares of Common Stock and accompanying Warrant to purchase one
share of Common Stock was $3.11 per set of securities, yielding an effective price of $1.55 per share and $0.01 per Warrant.

The Warrants will have an exercise price of $1.65 per share, subject
to adjustment as provided for therein, will be exercisable immediately and will be exercisable for a period of five years from the closing
of the Offering. The Warrants may only be exercised on a cashless basis if there is no registration statement registering, or the prospectus
contained therein is not available for, the issuance of the Warrant Shares to the holder. The Company is prohibited from effecting an
exercise of any Warrants to the extent that such exercise would result in the number of shares of Common Stock beneficially owned by such
holder and its affiliates exceeding 4.99% (or 9.99% at election of the holder) of the total number of shares of Common Stock outstanding
immediately after giving effect to the exercise, which percentage may be increased or decreased at the holder’s election not to
exceed 9.99%.

The net proceeds to the Company from the Offering are expected to be
approximately $6.3 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the
Company.

The Offering is being made pursuant to the Company’s effective
registration statement on Form S-3